Middletown, DE -- (SBWIRE) -- 10/28/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: LifeVantage Corp (NASDAQ:LFVN), PDL BioPharma Inc. (NASDAQ:PDLI), Dyax Corp. (NASDAQ:DYAX), Keryx Biopharmaceuticals (NASDAQ:KERX).
LifeVantage Corp (NASDAQ:LFVN), opened the session at $2.50, remained amid the day range of $2.49 - $2.62, and closed the session at $2.59. The stock showed a positive performance of 4.02% in previous trading session. The stock gained a volume of 1.48 million shares and the average volume of the stock remained 793,440 shares.
Will LFVN Continue To Move Higher? Find Out Here
LifeVantage Corporation identifies, researches, develops, and distributes nutraceutical dietary supplements and skin care products
PDL BioPharma Inc. (NASDAQ:PDLI), traded with volume of 1.45 million shares in the prior session and the average volume of the stock remained 1.71 million shares. The 52 week range of the stock remained $6.50 - $8.48. The stock showed a positive movement of 0.60% and closed its session at $8.41. The market capitalization of the stock remained 1.18 billion.
For How Long PDLI’s Gloss will Attract Investors? Find Out Here
PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities.
Dyax Corp. (NASDAQ:DYAX), exchanged 1.45 million shares and the average volume remained 1.30 million shares. The stock escalated2.50% and closed the session at $6.97. The beta of the stock remained 1.69 and the EPS of the stock remained -0.30. The shares outstanding of the stock remained 109.26 million.
Why Should Investors Buy DYAX After The Recent Gain? Find Out Here
Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded with volume of 1.45 million shares and the average volume of the stock remained 2.92 million shares. The stock grew0.19 % and finished the trading at $10.81. The market capitalization of the stock remained 884.43 million. The beta of the stock remained 3.84.
Will KERX Continue To Move Higher? Find Out Here
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)